Last reviewed · How we verify

Jiangsu XinChen-Techfields Pharma Co., LTD. — Portfolio Competitive Intelligence Brief

Jiangsu XinChen-Techfields Pharma Co., LTD. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Celecoxib capsules Celecoxib capsules phase 3 Selective COX-2 inhibitor (coxib) COX-2 (Cyclooxygenase-2) Rheumatology / Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Asker & Baerum Hospital · 1 shared drug class
  2. Chinese University of Hong Kong · 1 shared drug class
  3. Ferring Ventures Limited · 1 shared drug class
  4. Laboratorios Silanes S.A. de C.V. · 1 shared drug class
  5. Merck Sharp & Dohme LLC · 1 shared drug class
  6. National Eye Institute (NEI) · 1 shared drug class
  7. Novartis · 1 shared drug class
  8. Organon and Co · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu XinChen-Techfields Pharma Co., LTD.:

Cite this brief

Drug Landscape (2026). Jiangsu XinChen-Techfields Pharma Co., LTD. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-xinchen-techfields-pharma-co-ltd. Accessed 2026-05-16.

Related